<DOC>
	<DOCNO>NCT01327599</DOCNO>
	<brief_summary>The purpose study assess efficacy tolerability change DUOTRAV® prior bimatoprost 0.03 % /timolol 0.5 % pharmacotherapy subject open-angle glaucoma ocular hypertension uncontrolled intraocular pressure ( IOP ) .</brief_summary>
	<brief_title>Efficacy Changing DUOTRAV® From Prior Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Clinical diagnosis ocular hypertension , openangle pigment dispersion glaucoma least one eye . Stable IOPlowering regimen bimatoprost 0.03 % /timolol 0.5 % therapy ( either administer concomitantly fix combination ) within 4 week prior screen visit . IOP consider safe ( opinion investigator ) , eye , assure clinical stability vision optic nerve throughout study period . IOP 19 35 mmHg ( time day ) least one eye ( would designate study eye ) . Willing discontinue use ocular hypotensive medication ( ) prior receive study medication entire course study . Able follow instruction willing able attend study visit . Best correct visual acuity 6/60 ( 20/200 Snellen , 1.0 LogMAR ) good eye . Sign inform consent . Other protocoldefined inclusion criterion may apply . Known medical history allergy , hypersensitivity poor tolerance component DuoTrav® deem clinically significant opinion Principal Investigator . Corneal dystrophies either eye . Risk visual field visual acuity worsen consequence participation study , investigator 's best judgment . Bronchial asthma history bronchial asthma , bronchial hyper reactivity , severe chronic obstructive pulmonary disease would preclude safe administration topical betablocker . History severe allergic rhinitis . A condition , opinion Principal Investigator , would interfere optimal participation study , would present special risk subject . Participation investigational study within 30 day prior Screening Visit . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Open-angle glaucoma</keyword>
	<keyword>Ocular hypertension</keyword>
	<keyword>Pigment dispersion glaucoma</keyword>
	<keyword>Intraocular pressure</keyword>
</DOC>